Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Circulating tumor plasma cells as an independent prognostic marker in newly diagnosed multiple myeloma: Clinical correlation and immunophenotypic insights

View Full Paper
Ask AI
Bookmark
Share

Authors

JZJieqiong ZhouWYWenqiang YanJXJingyu Xu

Discussion

Loading...

Member takes

Overview

Analysis reveals circulating tumor plasma cells predict progression-free survival in multiple myeloma, suggesting immunophenotypic profiling for risk stratification.

Key Points

  • To investigate the clinical relevance and prognostic value of circulating tumor plasma cells in newly diagnosed multiple myeloma.
  • Retrospective analysis of 212 newly diagnosed multiple myeloma patients
  • Quantification of circulating tumor plasma cells using flow cytometry
  • Assessment of clinical parameters, cytogenetic risk, and treatment outcomes
  • Circulating tumor plasma cell levels correlated with high-risk disease features
  • Significant differences in progression-free survival based on circulating tumor plasma cell levels
  • Immunophenotypic profiling indicated differences between circulating and bone marrow plasma cells

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e012https://doi.org/10.1182/blood-2025-5761
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phenotypic evolution of circulating tumor plasma cells across MGUS, SMM and multiple myeloma2025
  2. 2Phenotypic evolution of circulating plasma cells from early precursor stages to multiple myeloma2026
  3. 3Baseline circulating tumor plasma cells are associated with progression-free survival in newly diagnosed multiple myeloma: a single-center real-world NGF study2026
  4. 4Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant2024 · 4 citations
  5. 5Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma2024 · 12 citations